Home  |  Contact

Cellosaurus SK-HEP-1 (CVCL_0525)

[Text version]

Cell line name SK-HEP-1
Synonyms SK-Hep-1; SK HEP-1; SK HEP 01; SK-Hep1; Sk-Hep1; SK Hep1; SKHEP-1; SKHEP1; SKHep1; SK_HEP1
Accession CVCL_0525
Resource Identification Initiative To cite this cell line use: SK-HEP-1 (RRID:CVCL_0525)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
From: Memorial Sloan Kettering Cancer Center; New York; USA.
Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-535.
Characteristics: Has lost chromosome Y.
Doubling time: 46.7 +- 10.3 hours, 94.2 hours (in CDM4-CHO medium), 289.8 hours (in 293 SFM II medium) (PubMed=25822314); ~30 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (PubMed=12068308; ATCC).
Homozygous for CDKN2A deletion (ATCC).
HLA typing Source: PubMed=9178645
Class I
HLA-AA*02:01,24:02
HLA-BB*44:03:01,35:04
HLA-CC*04:01
Class II
HLA-DQDQA1*01:02
DQB1*05:02,06.04
HLA-DRDRB1*13:02,16:02
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.65
Native American1.18
East Asian, North0
East Asian, South2.22
South Asian8.09
European, North23.66
European, South64.2
Disease Hepatocellular carcinoma (NCIt: C3099)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A040 (F2.4E5)CVCL_A041 (F2.5B6)CVCL_A042 (P1.1A3)
CVCL_A046 (P1.4D6)CVCL_XD84 (SK-HEP-1-Cas9-726)CVCL_XD85 (SK-HEP-1-Cas9-727)
CVCL_XD86 (SK-HEP-1-Cas9-728)CVCL_XD87 (SK-HEP-1-Cas9-729)CVCL_XD88 (SK-HEP-1-Cas9-730)
CVCL_XD89 (SK-HEP-1-Cas9-731)CVCL_XD90 (SK-HEP-1-Cas9-732)CVCL_XD91 (SK-HEP-1-Cas9-733)
CVCL_XD92 (SK-HEP-1-Cas9-734)CVCL_XD93 (SK-HEP-1-Cas9-735)CVCL_AU01 (SK-Hep-1-FIX)
CVCL_6019 (SK-Hep-1-NIS)CVCL_M182 (SK-Hep-1/CDDP)
Sex of cell Male
Age at sampling 52Y
Category Cancer cell line
STR profile Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; KCLB; MSKCC; PubMed=11416159; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,12 (ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; KCLB; MSKCC; PubMed=25877200)
11 (CLS)
D2S133820,23
D3S135816
D5S81810,13
D6S104311
D7S8208,11
D8S117913,14
D12S39118
D13S3178,12
D16S53912
D18S5113,15
D19S43312,15.2
D21S1129,31
FGA17
Penta D13,14
Penta E13,21 (CCRID; CLS)
13 (PubMed=25877200)
TH017,9
TPOX9
vWA14,17

Run an STR similarity search on this cell line
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-397.html
https://www.mskcc.org/research-advantage/support/technology/tangible-material/sk-hep-1-human-hepatic-adenocarcinoma-cell-line
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=432
http://www.cellresource.cn/fdetail.aspx?id=677
http://www.cellresource.cn/fdetail.aspx?id=901
http://www.cellresource.cn/fdetail.aspx?id=2790
Publications

DOI=10.1007/978-1-4757-1647-4_5
Fogh J., Trempe G.L.
New human tumor cell lines.
(In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=924690; DOI=10.1002/ijc.2910200505
Kerbel R.S., Pross H.F., Leibovitz A.
Analysis of established human carcinoma cell lines for lymphoreticular-associated membrane receptors.
Int. J. Cancer 20:673-679(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=1371504; DOI=10.1007/BF02631017
Heffelfinger S.C., Hawkins H.H., Barrish J., Taylor L., Darlington G.J.
SK HEP-1: a human cell line of endothelial origin.
In Vitro Cell. Dev. Biol. Anim. 28:136-142(1992)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)

PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=20069059; DOI=10.1155/2010/437143
Srisomsap C., Sawangareetrakul P., Subhasitanont P., Chokchaichamnankit D., Chiablaem K., Bhudhisawasdi V., Wongkham S., Svasti J.
Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes.
J. Biomed. Biotechnol. 2010:437143-437143(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=25822314; DOI=10.1007/s00449-015-1392-9
Biaggio R.T., Abreu-Neto M.S., Covas D.T., Swiech K.
Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation.
Bioprocess Biosyst. Eng. 38:1495-1507(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections ATCC; HTB-52
CCTCC; GDC0145
CLS; 300334/p485_SK-HEP-1
DSMZ; ACC-141
ECACC; 91091816
ICLC; HTL10001
KCB; KCB 2013038YJ
KCLB; 30052
Cell line databases/resources CLDB; cl4312
CLDB; cl4313
CLDB; cl4314
CLDB; cl4315
CLDB; cl7214
CCLE; SKHEP1_LIVER
CCRID; 3111C0001CCC000677
CCRID; 3111C0002000000060
CCRID; 3131C0001000700109
CCRID; 3142C0001000000133
Cell_Model_Passport; SIDM01110
CGH-DB; 9071-4
Cosmic-CLP; 909719
DepMap; ACH-000361
FCS-free; 174-2-331-1-4-3
GDSC; 909719
LINCS_LDP; LCL-1941
TOKU-E; 3132
Ontologies BTO; BTO:0003477
CLO; CLO_0009037
MCCL; MCC:0000425
Biological sample resources BioSample; SAMN01821598
BioSample; SAMN01821664
BioSample; SAMN03472884
BioSample; SAMN10988022
Chemistry resources ChEMBL-Cells; CHEMBL3307741
ChEMBL-Targets; CHEMBL614912
PharmacoDB; SKHEP1_1390_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM481451
GEO; GSM501784
GEO; GSM565878
GEO; GSM887578
GEO; GSM888661
GEO; GSM936776
GEO; GSM1374879
GEO; GSM1670432
Other Wikidata; Q54953666
Polymorphism and mutation databases Cosmic; 684195
Cosmic; 928139
Cosmic; 932990
Cosmic; 979728
Cosmic; 873394
Cosmic; 735607
Cosmic; 909719
Cosmic; 1187333
Cosmic; 1518231
Cosmic; 2162539
Cosmic; 2321042
Cosmic; 2668284
LiGeA; CCLE_110
Proteomic databases PRIDE; PXD002957
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number28